Lorantis, a UK-based emerging immunology drug discovery company, hasannounced the final closing of a L16.2 million ($23.6 million) second-round financing, having received a further L4.7 million from new investors The Wellcome Trust and Northern Venture Managers and existing shareholder Quester. This round follows an initial L11.5 million received earlier this year when JP Morgan Partners led a financing which also included continuing investors Abingworth and Schroder Ventures (Marketletter April 30).
Firm offers "enormous opportunities"
The proceeds will be used to support ongoing research programs within the tolerance field of immunology. Chief executive Mark Bodmer said that the closing of this round is an important milestone for the company, which was established in 1998, and stated his delight "that such high-quality life sciences investors recognize the enormous opportunity that Lorantis offers.''
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze